<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03941340</url>
  </required_header>
  <id_info>
    <org_study_id>20190130</org_study_id>
    <nct_id>NCT03941340</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Mass Balance And Biotransformation of Single Dose[14C] AST2818 in Chinese Healthy Male Volunteers</brief_title>
  <official_title>A Phase I Mass Balance and Biotransformation Study of Orally Administered [14C]-Alflutinib Mesylate (AST2818) in Chinese Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allist Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allist Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to Evaluate the Mass Balance and Biotransformation of Single Dose[14C] AST2818 in&#xD;
      Chinese Healthy Male Volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I Mass Balance and Biotransformation Study of Orally Administered [14C]-Alflutinib&#xD;
      Mesylate (AST2818) in Chinese Healthy Male Volunteers&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 8, 2019</start_date>
  <completion_date type="Actual">September 6, 2019</completion_date>
  <primary_completion_date type="Actual">September 6, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The distribution of AST2818 in the whole blood and plasma and whole radioactive pharmacokinetics following the single orally administered [14C]-AST2818 in healthy male volunteers.</measure>
    <time_frame>Blood samples (hrs) - 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, every 24 to 504, 672, 840, 1008, 1176, 1344, 1512, 1680, 1848 and 2016.</time_frame>
    <description>The percentage of radioactive dose of [14C] radiolabelled AST2818 recovered in blood and in total, up to Day 85（p.s:The administration time on the first day is 7:30 am）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitive analysis of whole radioactivity of excrement of orally administered [14C]-AST2818 in healthy volunteers to obtain the mass balance data and the main excretion pathway in human body.</measure>
    <time_frame>Urine and faeces (hrs): 0-4, 4-8, 8-12, 12-24, every 24 to 504, 624-672, 792-840, 960-1008, 1128-1176, 1296-1344, 1464-1512, 1632-1680, 1800-1848 and 1968-2016.</time_frame>
    <description>The percentage of radioactive dose of [14C] radiolabelled AST2818 recovered in urine, faeces and in total, up to Day 85（p.s:The administration time on the first day is 7:30 am）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitive analysis of the concentrations of AST2818 and AST5902 (Metabolite of AST2818) in plasma using the validated LC-MS/MS to obtain pharmacokinetic data;</measure>
    <time_frame>Blood samples (hrs) - 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, every 24 to 504, 672, 840, 1008, 1176, 1344, 1512, 1680, 1848 and 2016.</time_frame>
    <description>The concentrations of AST2818 and AST5902 in plasma up to Day 85（p.s:The administration time on the first day is 7:30 am）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of different metabolites in healthy volunteers after oral administration of [14C]-AST2818</measure>
    <time_frame>Blood samples (hrs) - 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, every 24 to 504, 672, 840, 1008, 1176, 1344, 1512, 1680, 1848 and 2016.</time_frame>
    <description>Proportion of different metabolites</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Types of adverse events assessed by CTCAE v5.0 that occurred during the trial</measure>
    <time_frame>Baseline (Day-1) to Day 85（p.s:The administration time on the first day is 7:30 am）</time_frame>
    <description>Types of adverse events</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Male Volunteers</condition>
  <arm_group>
    <arm_group_label>[14C]-AST2818 80mg (oral solution)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive 80 mg [14C]-AST2818 containing a nominal 100 μCi activity, administered by mouth, as a solution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14]-AST2818</intervention_name>
    <description>Volunteer will receive a single oral dose of 80 mg /100 u Ci [14C]-AST2818 as a solution on Day 1</description>
    <arm_group_label>[14C]-AST2818 80mg (oral solution)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult;&#xD;
&#xD;
          2. Body weight: The body mass index varies in the range of 19 - 26 kg/m2 (including 19&#xD;
             and 26 kg/m2);&#xD;
&#xD;
          3. Signing the informed consent forms by oneself ;&#xD;
&#xD;
          4. Be able to communicate well with the researcher and be able to complete the trial in&#xD;
             accordance with the program.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those with abnormal examination and clinical significance ( including Physical&#xD;
             examination, routine laboratory examination (blood routine, urine routine, fecal&#xD;
             routine + Occult blood, blood biochemistry, blood coagulation routine, thyroid&#xD;
             function), 12-lead electrocardiogram, X-ray (positive position), abdominal B-mode&#xD;
             ultrasonography (liver, gallbladder, pancreas, spleen and kidney), etc)；&#xD;
&#xD;
          2. Those with routine urine examination showed positive urinary protein；&#xD;
&#xD;
          3. Those with QTcF &gt; 470 msec in resting state, corrected by ECG during screening period；&#xD;
&#xD;
          4. Those with HBsAg , HBeAg and HCVAb were positive；&#xD;
&#xD;
          5. Those with HIVAb was positive；&#xD;
&#xD;
          6. Those with treponema pallidum Ab was positive；&#xD;
&#xD;
          7. Those who take any drugs that inhibit or induce the CYP450 enzyme (i.e., inducers-&#xD;
             barbiturates, tegretol, phenytoin, rifampicin, hexadecadrol, rifabutin, rifapentini;&#xD;
             inhibitors- SSRI-antidepressant, cimetidine, diltiazem, macrolides, verapamil,&#xD;
             imidazoles- antifungal drugs) 30 days prior to screening period；&#xD;
&#xD;
          8. Those who take any drug, health care products (including vitamins), chinese&#xD;
             traditional medicine 14 days prior to screening period；&#xD;
&#xD;
          9. Those who participated other clinical trials or took the investigational drug 3 months&#xD;
             prior to screening period, or prepare to take part in other clinical trials within 1&#xD;
             month after finishing this trial；&#xD;
&#xD;
         10. Those who have history of organic heart disease, heart failure, myocardial infarction,&#xD;
             angina, unexplained arrhythmia, torsional ventricular tachycardia, ventricular&#xD;
             tachycardia and QT prolonged syndrome, or have the family history (Genetic proof or a&#xD;
             close relative of sudden cardiac death at a young age) and symptom of QT prolonged&#xD;
             syndrome ；&#xD;
&#xD;
         11. Those who have severe disease of ophthalmic system, e.g., corneal, conjunctiva and&#xD;
             eyelid diseases;&#xD;
&#xD;
         12. Those who have undergone major surgery within the first 6 months of the screening&#xD;
             period or have no complete surgical incision; major procedures include, but are not&#xD;
             limited to, any operator with significant bleeding risk, prolonged general anesthesia,&#xD;
             or incisional biopsy or significant traumatic injury;&#xD;
&#xD;
         13. Those who have but not limited to circulatory system, endocrine system, nervous&#xD;
             system, digestive system, urinary system, or have the history of blood, immunity&#xD;
             spirit and metabolism diseases；&#xD;
&#xD;
         14. Those who have allergic constitution, including being definitely allergic to TKIs or&#xD;
             any ingredients of this trial drugs，any food materials or have special demands for&#xD;
             foods，and cannot comply with the rule of unified diet；&#xD;
&#xD;
         15. Those who have history of hand and foot syndrome；&#xD;
&#xD;
         16. Those who have haemorrhoids or perianal disease with regular/ongoing hematochezia；&#xD;
&#xD;
         17. Those who have coagulation dysfunction or other diseases of the blood system;&#xD;
&#xD;
         18. Those who have history of tumor；&#xD;
&#xD;
         19. Those who have habitual constipation or diarrhea, irritable bowel syndrome,&#xD;
             inflammatory bowel disease；&#xD;
&#xD;
         20. Those who have history of alcohol abuse (it was defined as that the daily alcohol&#xD;
             consumption was higher than the following criteria: the weekly alcohol consumption was&#xD;
             higher than 14 units of alcohol (1 unit= 360 ml beers/45 ml liquor containing 40%&#xD;
             alcohol/150ml grape wine) 6 months prior to screening period, or the alcohol breath&#xD;
             test results ≥20 mg/dl during screening period；&#xD;
&#xD;
         21. Those who smoked daily &gt;5 sticks of cigarette 3 months prior to first dose or cannot&#xD;
             give up smoking during study；&#xD;
&#xD;
         22. Those have history of drug abuse or taking soft drug (i.e., marihuana) 3 months prior&#xD;
             to screening period or taking hard drugs (i.e., cocaine, amphetamines, benzodiazepine,&#xD;
             etc.); or the results of urine test in drugs were positive;&#xD;
&#xD;
         23. Those who were used to drink grapefruit juice or overconsumption of tea, coffee, and&#xD;
             the drink with caffeine; and cannot give up them during test；&#xD;
&#xD;
         24. Those who need long-term exposure to radiation, or who have been exposed to&#xD;
             significant radiation (&gt; 2 chest/abdominal CT scans or more than 3 other X-ray scans)&#xD;
             or who have participated in the labeling test of radiopharmaceuticals within one year&#xD;
             before the test;&#xD;
&#xD;
         25. Those who have fertility planning within the range of starting trial - 1 year after&#xD;
             finishing trial, or disagree with the regulation and their mate should take strict&#xD;
             contraception (taking condoms, contraceptive sponges, contraceptive gels,&#xD;
             contraceptive membranes, intrauterine devices, oral or injectable contraceptives and&#xD;
             subcutaneous implants, etc.)；&#xD;
&#xD;
         26. Those who have excessive bleeding or blood donation (400ml) 3 months prior to&#xD;
             screening period, or planned to donate blood 1 month after finishing this trial；&#xD;
&#xD;
         27. Those who cannot complete this study because of other reasons, or any factors judged&#xD;
             by investigator that the participants cannot meet.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LiYan Miu</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 24, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>January 2, 2020</last_update_submitted>
  <last_update_submitted_qc>January 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflutinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

